EP1485081B1 - Ibuprofen solution for hard shell capsules - Google Patents

Ibuprofen solution for hard shell capsules Download PDF

Info

Publication number
EP1485081B1
EP1485081B1 EP03743950A EP03743950A EP1485081B1 EP 1485081 B1 EP1485081 B1 EP 1485081B1 EP 03743950 A EP03743950 A EP 03743950A EP 03743950 A EP03743950 A EP 03743950A EP 1485081 B1 EP1485081 B1 EP 1485081B1
Authority
EP
European Patent Office
Prior art keywords
weight
ibuprofen
castor oil
polyoxyl
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03743950A
Other languages
German (de)
French (fr)
Other versions
EP1485081A1 (en
Inventor
E. M. Emmanuelle Mireille GUILLARD
Nicolas Madit
Robert A. Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to EP03743950A priority Critical patent/EP1485081B1/en
Publication of EP1485081A1 publication Critical patent/EP1485081A1/en
Application granted granted Critical
Publication of EP1485081B1 publication Critical patent/EP1485081B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to pharmaceutically acceptable and stable compositions, which are preferably clear transparent, for liquid filling hard shell capsules, hard shell capsules containing these compositions, and a process for preparing these hard shell capsules and whereby the shells of said hard capsules are preferably clear transparent.
  • Ibuprofen (2-(4-isobutylphenyl)propionic acid is a drug which has anti-inflammatory and analgesic properties. It is used for the treatment of rheumatoid arthritis or other inflammatory diseases of joints, soft tissue rheumatism and gout.
  • a medicament suitable to combat acute pain is demanded to display its effects fast which is only achieved by a quick release and good bio-availability of the active ingredient.
  • Ibuprofen although it is soluble in some physiologically compatible solvents, will immediately precipitate upon the addition of small amounts of water or when the solution is introduced into an aqueous medium as for example an artificial gastric juice. When such a solution, upon oral administration, gets into the stomach, the ibuprofen precipitates so that it will be barred from a quick resorption.
  • US 4,690,823 describes soft gelatin capsules containing a solution of from 15 to 30 parts by weight of ibuprofen in from 70 to 85 parts by weight of polyoxyethylene-polyoxypropylene polymer or in a mixture of from 30 to 76 parts by weight of olyalkylene glycol and from 7 to 40 parts by weight of a surfactant. These capsules are described to have a very rapid and high bio-availability of the active ingredient. The active ingredient is not reprecipitated therefrom by aqueous media such as artificial gastric juice.
  • US 4,690,823 furthermore discloses that ibuprofen may be readily dissolved in polyoxyethylene-polyoxypropylene polymer or in a mixture of a polyalkylene glycol and a surfactant at a temperature of from 45°C to 65°C and will remain in solution upon cooling to room temperature. No precipiation occurs when these solutions are introduced in an aqueous medium, more specifically into artificial gastric juice, so that the ibuprofen can be quickly and completely resorbed from this solution. Ibuprofen is used in an amount of up to 40 % ibuprofen. No alkali hydroxide is added. In the examples polyoxyethylene-(40)[and-(60]-glycerol trihydroxystearate are used as surfactant.
  • US 6,096,338 discloses a carrier system for a hydrophobic drug which comprises a) a digestible oil, b) a pharmaceutically acceptable surfactant, wherein the surfactant comprises a hydrophilic surfactant component which substantially inhibits the in vivo lipolysis of said digestible oil, and a lipophilic surfactant component capable of at least substantially reducing said inhibitory effesct of said hydrophilic surfactant component.
  • Miglyol ® 812 is disclosed as being often a preferred medium chain fatty acid triglyceride oil. Any pharmaceutically acceptable hydrophilic surfactants can be used.
  • Cremophor ® EL and Cremophor ® RH40 are mentioned as examples for the hydrophilic surfactant.
  • US 5,141,961 relates to a process for solubilizing at least one difficultly soluble pharmaceutical active in a mixture of polyethylene glycol and polyvinylpyrrolidone.
  • WO 96/19202 discloses a solvent system for enhancing the solubility of ibuprofen which comprises as an ibuprofen solubility enhancer about 1 % to 10 % by weight of ammonium acetate.
  • the solvent system is a pharmaceutically acceptable highly concentrated clear microcolloidal solution of ibuprofen suitable for filling soft gels for oral administration comprising, based on the weight of the clear solution, at least about 25 % by weight of ibuprofen, about 1% to 10% by weight of water and about 50 % to 74 % by weight of at least one pharmaceutically acceptable solubilizing material selected from among non-ionic polyethoxylated surface active agents having a hydrophile lipophile balance within the range of 8 to 25, alone or in combination with a solvent system having a solubility parameter within the range of from 8.0 and 15.0.
  • WO 92/20334 discloses the use of S(-)sodium 2-(-isobutylphenylpropionate (the sodium salt of S(+)ibuprofen) in pharmaceutical compositions for the treatment of inflammation, pain and pyrexia.
  • Liquid fill compositions suitably comprise a) 10-80% S (-) sodium 2-(4-isobutylphenyl)propionate and b) 20-90 % of a fatty acid ester excipient which comprises one or more polyol esters and triglycerides of natural vegetable oil fatty acids.
  • WO 00/30619 discloses a self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith.
  • the solution provides a self-emulsifying ibuprofen formulation including a polyoxyethylene castor oil derivative and ibuprofen which increases the stability, concentration, and bioavailability of the scarcely water soluble ibuprofen.
  • the amount of the polyoxyethylene castor oil derivatives ranges from approx. 30% to approx. 35% by weight.
  • the hydrophobic constituents comprise approx. 83% of the total mixture with the main component being glycerolpolyethylene glycol ricinoleate.
  • the hydrophilic component (ca. 17 %) consists of polyethylene glycols and glycerol ethoxylates.
  • the hydrophobic component is app. 75% of the total mixture.
  • the hydrophobic component is comprised mainly of fatty acid esters of glycol polyethylene glycol and fatty esters of polyethylene glycol.
  • the hydrophilic fraction (ca. 25 %) consists of polyethylene glycols and glycerol ethoxylates.
  • ibuprofen in the formulation ranges from approx 33% to 38 % by weight.
  • WO 00/30619 suggests to enhance and stabilize solution concentrations at ambient temperatures by the addition of complexing agents like soluble polyvinyl pyrrolidone (PVP).
  • the drug delivery vehicle of WO 00/30619 can be a two-piece, standard gelatin capsule, but is more preferably a soft gelatin capsule which is a one-piece, hermetically sealed gelatin capsule.
  • EP 0 413 171 B1 discloses agents for the treatment of conditions of severe pain consisting of soft gelatine capsules containing from 30 to 50 parts ibuprofen and from 1.5 to 4 parts bei weight of codein and/or physiologically compatible salts thereof, partially dissolved and partially suspended in 68.5 to 46 parts by weight of polyoxyethylene-polyoxypropylene-diol or in a mixture comprising 30 to 76 parts by weight of polyoxyethylene-polyoxypropylene-diol or polyethyleneglycol or polypropyleneglycol and from 7 to 40 parts by weight of a physiologically compatible surfactant.
  • US-A-5,360,615 discloses a solvent system enhancing the solubility of pharmaceuticals for encapsulation, in particular, for enhancing the solubility of an acidic pharmaceutical agent like ibuprofen to produce a highly concentrated solution suitable for softgel filling comprising 10-80 % polyethylene glycol, a. solubility enhancing amount of either hydroxide or hydrogen ion and 1-20 % by weight of water.
  • a solvent system enhancing the solubility of pharmaceuticals for encapsulation, in particular, for enhancing the solubility of an acidic pharmaceutical agent like ibuprofen to produce a highly concentrated solution suitable for softgel filling comprising 10-80 % polyethylene glycol, a. solubility enhancing amount of either hydroxide or hydrogen ion and 1-20 % by weight of water.
  • the solution of ibuprofen disclosed in US 5,360,615 as being suitable for filling softgels or two piece capsules, or for tablet formation comprises 40-80 % by weight ibuprofen, 0.1 - 1.5 moles of hydroxide ion per mole of ibuprofen, 1-20 % by weight water, and 4-12 % by weight glycerin or propylene glycol in polyethylene glycol, wherein said hydroxide ion is more preferredly in the range of 0.2-0.5 moles of hydroxide ion per mole of ibuprofen.
  • US-A-5 912 011 discloses a high concentration solvent system to be enclosed in capsules, said system being composed of a) 10-80% by weight acidic medicine, b) 0.1-1.0 mole hydroxide ions for one mole of said medicine, and c) 1-20% by weight water included in polyoxyethylene sorbitan fatty acid ester.
  • US-A-5 376 688 discloses solutions containing acidic, basic and/or amphoteric pharmaceutical agents for encapsulation in gelatin capsules that derive from the Yu, et al. US patent No. 5,071,643 .
  • US patent No. 5,071,643 discloses a solvent system for enhancing the solubility of an acidic pharmaceutical agent to produce a highly concentrated solution suitable for soft gel filling comprising 10-80% polyethylene glycol, a solubility enhancing amount of hydroxide ion, preferably 0.2-1.0 mole equivalents of hydroxide ion per mole equivalent of acid in an acidic pharmaceutical agent, and 1-20% by weight of water.
  • US-A-5 376 688 provides that water may be included in the solution up to about 20% by weight of the solution, More preferably between about 1% up to about 10% by weight of the solution.
  • D2 further discloses that the pharmaceutically acceptable solution can be encapsulated into conventional soft gelatin capsules in accordance with the rotary die process. Alternatively, semi-solid or solid solutions can be appropriately encapsulated in hard shell gelatin capsules as well as soft gelatin capsules. All the examples disclose filling soft gelatin capsules.
  • Example 5 discloses aqueous compositions but does not precise what kind of capsules are filled with the compositions.
  • the filled capsules should be usable as medicaments that can be readily taken and that may contain high concentrations of ibuprofen in a carrier, that are simple to prepare and that will quickly display a high activity.
  • the solutions for filling hard gelatin capsules should show an increased stability and bioavailability of ibuprofen.
  • Hard shell capsules are two piece pharmaceutical capsules with shells consisting generally of known film forming materials or compositions.
  • Suitable film forming material can be a hydrophilic polymer, gelatin being the preferred choice.
  • Other suitable capsule shell materials include starch, modified starches like hydroxypropylated hydroxyethylated starches, casein, chitosan, soya bean protein, safflower protein, alginates, gellan gum, carrageenan, xanthan gum, pullulan, phthalated gelatin, succinated gelatin, cellulosephtalate-acetate, polyvinylalcohol, polyvinylacetate, hydroxypropyl methylcellulose, polyvinylacetate-phtalate, polymerisates of acrylic or mthacrylic esters or mixtures thereof.
  • the capsule shell material may furthermore contain 0 to 40 % pharmaceutically acceptable plasticizers based upon the weight of the hydrophilic polymer.
  • the plasticizer which may be employed can be selected from polyethylene glycol, glycerol, sorbitol, dioctyl-sodium sulfosuccinate, triethyl citrate, tributyl citrate, 1,2-propyleneglycol, mono-, di, or tri-acetates of glycerol or mixtures thereof.
  • the capsule shell material can contain 0 to 10 % pharmaceutically acceptable lubricants based upon the weight of the hydrophilic polymer.
  • the lubricate may be selected from aluminiumstearate, calciumstearate, magnesiumstearate, tinstearate, talc, sodium lauryl sulfate, lecithins, mineral oils, stearic acid or silicones or mixtures thereof.
  • the capsule shell material can contain 0 to 10 % pharmaceutically acceptable coloring agents based upon the weight of the hydrophilic polymer.
  • the coloring agent may be selected from azo-quinophthalone-, triphenylmethane-, xanthene-dyes, iron oxides or hydroxides, titanium dioxide or natural dyes or mixtures thereof. Further suitable coloring agents are sunset yellow, allura red, amaranth, cochineal red, azogeranine, tartrazine, brilliant black, canthaxanthin, patent blue, fast green, brilliant blue, acid green, erythrosine, quinoline yellow, indigotine, curcumin or carbon black.
  • the capsule shell material contains 0 to 95 % pharmaceutically acceptable extenders based upon the weight of the hydrophilic polymer.
  • the extender may be selected from sunflower proteins, soybean proteins, cotton seed proteins, peanut proteins, rape seed proteins, lactose, gum arabic, acrylates or methacrylates, cellulose acetyl phthalates, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulosephthalate, hydroxymethylcellulose, polyvinylpyrrolidone, shellac, bentonite, polyvinyl-acetatephtalate, phthalated gelatin, succinated gelatin, agar agar, hydroxyalkylstarches or mixtures thereof.
  • the solid pharmaceutical dosage form according to the present invention also may comprise a coating selected from cellacephate, polyvinyl acetate phthalate, methacrylic acid polymers, hypromellose phthalate, hydroxyalkyl methyl cellulose phthalates or mixtures thereof.
  • the film forming composition is suitable for the manufacture of clear transparent hard capsules by conventional dip molding process on high speed production equipment.
  • the present invention provides pharmaceutically acceptable solutions, which are preferably clear transparent, for filling hard shell capsules comprising, based upon the total weight of the solution,
  • the present invention furthermore provides an ibuprofen-containing hard shell capsule, preferably clear transparent, containing a solution which comprises, based upon the total weight of the solution,
  • ibuprofen is used according to the invention in an amount of from 35 to 75 % by weight, preferably 40 to 55 % by weight, most preferably 45 to 50 by weight, with respect to the total weight of the solution.
  • ibuprofen is in general used as racemic mixture.
  • alkali hydroxide is used in an amount of from 1 to 10 % by weight, preferably 1 to 5 % by weight, with respect to the total weight of the solution.
  • the alkali hydroxide used as component b) in the present invention is preferably sodium hydroxide (NaOH), potassium hydroxide (KOH) or their mixture.
  • the most preferred alkali hydroxide according to the invention is KOH.
  • KOH is used in an amount of from 0.2 to 0.35 moles per mol ibuprofen, i.e., 0.2 to 0.35 mole equivalents of alkali hydroxide per mole of the pharmaceutical agent ibuprofen.
  • component c) As component c) according to the invention 15 to 55 % by weight, with respect to the total weight of the solution, emulsifiers selected from polyoxyethylene alkyl ethers, medium chain triglycerides, propylene glycol esters, glyceryl esters, sorbitan esters, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, or mixtures therof are used.
  • emulsifiers selected from polyoxyethylene alkyl ethers, medium chain triglycerides, propylene glycol esters, glyceryl esters, sorbitan esters, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, or mixtures therof are used.
  • Preferred polyoxethylene alkyl ethers according to the invention are polyoxyl 2 cetyl ether, polyoxyl 10 cetyl ether, polyoxyl 20 cetyl ether, polyoxyl 4 lauryl ether, polyoxyl 23 lauryl ether, polyoxyl 2 oleyl ether, polyoxyl 10 oleyl ether, polyoxyl 20 oleyl ether, polyoxyl 2 stearyl ether, polyoxyl 10 stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 100 stearyl ether or polyoxyl 20 cetostearyl ether.
  • Preferred medium chain triglycerides are caprylic/capric triglycerides like MTC oil, Miglyol ® 810 or Miglyol ® 812. Especially preferred is Miglyol ® 812.
  • Preferred propylene glycol ester are propylene glycol propylene glycol dicocoate, propylene glycol distearate, propylene glycol dioctanoate, propylene glycol dipelargonate, propylene glycol diundecanoate, propylene glycol monostearate, propylene glycol monohydroxystearate, propylene glycol monolaurate, propylene glycol monomyristate, or propylene glycol monooleate.
  • propylene glycol monolaurate is especially preferred.
  • Preferred glyceryl esters are glyceryl monooleate, glyceryl monostearate or glyceryl palmitostearate. Especially preferred is glyceryl monooleate.
  • Preferred sorbitan ester are sorbitan di-isostearate, sorbitan dioleate, sorbitan monolaurate, sorbitan monoisostearate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesqui-isostearate, sorbitan sesquioleate, sorbitan sesquistearate, sorbitan tri-isostearate, sorbitan trioleate or sorbitan tristearate.
  • sorbitan trioleate is especially preferred.
  • Preferred polyoxyethylene castor oil derivatives are polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, polyoxyl 40 castor oil, polyoxyl 40 hydrogenated castor oil or polyoxyl 60 hydrogenated castor oil.
  • polyoxyl 35 castor oil (Cremophor ® EL) or polyoxyl 40 hydrogenated castor oil (Cremophor ® RH40).
  • Preferred polyoxyethylene sorbitan fatty acid esters are polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polysorbate 81, polysorbate 85 or polysorbate 120. Especially preferred is polysorbate 60.
  • Preferred polyoxyethylene stearates are polyoxyl 6 stearate, polyoxyl 8 stearate, polyoxyl 12 stearate or polyoxyl 20 stearate.
  • the density of the emulsifier c) may vary over a broad range, but is generally in the range of from 0.85 to 1.1 at 60°C.
  • the emulsifier c) is a polyoxyethylene castor oil derivative, especially preferred polyoxyl 35 castor oil (Cremophor ® EL) or polyoxyl 40 hydrogenated castor oil (Cremophor ® RH40) in an amount of from 40 to 55, in particular 45 to 50 % by weight of the whole composition.
  • the polyoxyethylene castor oil derivative is used in an amount from 10 to 40 %, more preferably from 15 to 35 % by weight in admixture with medium chain triglycerides from 7 to 35 % by weight, preferably 10 to 25 % by weight, most preferably 12 to 18 % by weight of the whole composition and whereby the caprylic/capric triglyceride Miglyol ® 812 is especially preferred.
  • the solution according to the present invention comprising components a), b) and c) and/or water and/or other ingredients is preferably clear transparent and has in general a viscosity at 25°C in the range of from 500 to 5000 cps, preferably of from 1000 to 4000 cps, and most preferably of from 1200 to 2500 cps.
  • the present invention provides an ibuprofen-containing hard shell capsule containing the aforementioned solution comprising components a) to c) and/or water and/or other ingredients.
  • the hard shell capsule is a system comprised of the ibuprofen formulation and the capsule shell used to encapsulate the ibuprofen formulation.
  • the shell composition is also critical as it must be compatible with the ibuprofen formulation.
  • the potential fill-shell interactions could result in both physical and chemical capsule instability. Accordingly, the shell composition utilized to form the capsule for the ibuprofen dosage form is also critical to the present invention.
  • the present invention utilizes a hard shell capsule consisting of the aforementioned film forming material.
  • the capsule of the present invention is clear transparent.
  • Hard shell capsules for liquid filling have usually a volume of from 0.3 to 1.0 ml.
  • the available volume is in general from 85-95 vol-%.
  • the moisture uptake of hard shell capsules is usually much lower than of soft capsules.
  • the capsule In the hard capsule encapsulation process the capsule is usually pre-fabricated and supplied empty, whereas in the soft capsule the encapsulation and filling take place simultaneously.
  • Preferred methods ar banding using a band consisting of a film forming material as aforementioned for the capsul shell, and sealing using a hydroalcoholic solution.
  • the banding of hard shell capsules is well-known in the art.
  • the capsules are first rectified and then passed once or twice over a whell that revolves in a gelatin bath. An amount of gelatin is picked up by the serrated wheel and applied to the junction of the cap and body. The capsules remain in individual carries for drying.
  • the hard shell capsule sealing is preferred which is based upon the lowering of the melting point of gelatin by the application of moisture to the area between the capsule body and cap.
  • a method is thus contemplated where the capsules are filled and then sealed by spraying a small amount of a water/ethanol mixture at the cap and body interface followed by warming to fuse the two capsule part together.
  • Instrumentation for performing the encapsulation according to the above methods is commercially available.
  • the capsules of the present invention did not show any capsule brittleness as determined according to Cadé and Madit, in "Liquid Filling in Hard Gelatin Capsules - Preliminary Steps", Bulletin Technique Gattefossé, 1996 , when stored at 30% and 50% relative humidity for four weeks.
  • ibuprofen in a two piece hard shell capsule, wherein the fill solution contains a therapeutically effective amount of ibuprofen dissolved within.
  • the dosages administered will vary depending upon the acidic pharmaceutical agent employed, the mode of administration the treatment desired, the size, age, and weight of the patient being treated and the like.
  • Example 1 0.3 mol equiv KOH and 15 % Miglyol ® were used. The viscosity at 25°C was 1900 cps and at 35°C 836 cps.
  • Example 2 0.3 mol equiv KOH/ 15 % Miglyol ® were used. The viscosity was 3140 cp at 25 °C.
  • Example 3 mg/caps % Ibuprofen 201.78 48.04 Cremophor® EL or RH 40 201.78 48,04 Miglyol® 812 - - KOH 16.44 3,92 420.00 100

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutically acceptable solutions for filling hard gelatin capsules, hard gelatin capsules containing these solutions.

Description

  • The present invention relates to pharmaceutically acceptable and stable compositions, which are preferably clear transparent, for liquid filling hard shell capsules, hard shell capsules containing these compositions, and a process for preparing these hard shell capsules and whereby the shells of said hard capsules are preferably clear transparent.
  • Ibuprofen (2-(4-isobutylphenyl)propionic acid is a drug which has anti-inflammatory and analgesic properties. It is used for the treatment of rheumatoid arthritis or other inflammatory diseases of joints, soft tissue rheumatism and gout.
  • In general, a medicament suitable to combat acute pain is demanded to display its effects fast which is only achieved by a quick release and good bio-availability of the active ingredient.
  • Ibuprofen, although it is soluble in some physiologically compatible solvents, will immediately precipitate upon the addition of small amounts of water or when the solution is introduced into an aqueous medium as for example an artificial gastric juice. When such a solution, upon oral administration, gets into the stomach, the ibuprofen precipitates so that it will be barred from a quick resorption.
  • US 4,690,823 describes soft gelatin capsules containing a solution of from 15 to 30 parts by weight of ibuprofen in from 70 to 85 parts by weight of polyoxyethylene-polyoxypropylene polymer or in a mixture of from 30 to 76 parts by weight of olyalkylene glycol and from 7 to 40 parts by weight of a surfactant. These capsules are described to have a very rapid and high bio-availability of the active ingredient. The active ingredient is not reprecipitated therefrom by aqueous media such as artificial gastric juice.
  • US 4,690,823 furthermore discloses that ibuprofen may be readily dissolved in polyoxyethylene-polyoxypropylene polymer or in a mixture of a polyalkylene glycol and a surfactant at a temperature of from 45°C to 65°C and will remain in solution upon cooling to room temperature. No precipiation occurs when these solutions are introduced in an aqueous medium, more specifically into artificial gastric juice, so that the ibuprofen can be quickly and completely resorbed from this solution. Ibuprofen is used in an amount of up to 40 % ibuprofen. No alkali hydroxide is added. In the examples polyoxyethylene-(40)[and-(60]-glycerol trihydroxystearate are used as surfactant.
  • US 6,096,338 discloses a carrier system for a hydrophobic drug which comprises a) a digestible oil, b) a pharmaceutically acceptable surfactant, wherein the surfactant comprises a hydrophilic surfactant component which substantially inhibits the in vivo lipolysis of said digestible oil, and a lipophilic surfactant component capable of at least substantially reducing said inhibitory effesct of said hydrophilic surfactant component. Miglyol® 812 is disclosed as being often a preferred medium chain fatty acid triglyceride oil. Any pharmaceutically acceptable hydrophilic surfactants can be used. Among numerous examples Cremophor® EL and Cremophor® RH40 are mentioned as examples for the hydrophilic surfactant.
  • US 5,141,961 relates to a process for solubilizing at least one difficultly soluble pharmaceutical active in a mixture of polyethylene glycol and polyvinylpyrrolidone.
  • WO 96/19202 discloses a solvent system for enhancing the solubility of ibuprofen which comprises as an ibuprofen solubility enhancer about 1 % to 10 % by weight of ammonium acetate. The solvent system is a pharmaceutically acceptable highly concentrated clear microcolloidal solution of ibuprofen suitable for filling soft gels for oral administration comprising, based on the weight of the clear solution, at least about 25 % by weight of ibuprofen, about 1% to 10% by weight of water and about 50 % to 74 % by weight of at least one pharmaceutically acceptable solubilizing material selected from among non-ionic polyethoxylated surface active agents having a hydrophile lipophile balance within the range of 8 to 25, alone or in combination with a solvent system having a solubility parameter within the range of from 8.0 and 15.0.
  • WO 92/20334 discloses the use of S(-)sodium 2-(-isobutylphenylpropionate (the sodium salt of S(+)ibuprofen) in pharmaceutical compositions for the treatment of inflammation, pain and pyrexia. Liquid fill compositions suitably comprise a) 10-80% S (-) sodium 2-(4-isobutylphenyl)propionate and b) 20-90 % of a fatty acid ester excipient which comprises one or more polyol esters and triglycerides of natural vegetable oil fatty acids.
  • WO 00/30619 discloses a self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith. The solution provides a self-emulsifying ibuprofen formulation including a polyoxyethylene castor oil derivative and ibuprofen which increases the stability, concentration, and bioavailability of the scarcely water soluble ibuprofen. The amount of the polyoxyethylene castor oil derivatives ranges from approx. 30% to approx. 35% by weight.
  • In one preferred embodiment of the polyoxyethylene castor oil derivatives of WO 00/30619 the hydrophobic constituents comprise approx. 83% of the total mixture with the main component being glycerolpolyethylene glycol ricinoleate. The hydrophilic component (ca. 17 %) consists of polyethylene glycols and glycerol ethoxylates.
  • In another preferred embodiment of the polyoxyethylene castor oil derivatives of WO 00/30619 the hydrophobic component is app. 75% of the total mixture. The hydrophobic component is comprised mainly of fatty acid esters of glycol polyethylene glycol and fatty esters of polyethylene glycol. The hydrophilic fraction (ca. 25 %) consists of polyethylene glycols and glycerol ethoxylates.
  • The amount of ibuprofen in the formulation ranges from approx 33% to 38 % by weight. In order to prevent the recrystallization of ibuprofen from the solution upon cooling, WO 00/30619 suggests to enhance and stabilize solution concentrations at ambient temperatures by the addition of complexing agents like soluble polyvinyl pyrrolidone (PVP).
  • The drug delivery vehicle of WO 00/30619 can be a two-piece, standard gelatin capsule, but is more preferably a soft gelatin capsule which is a one-piece, hermetically sealed gelatin capsule.
  • EP 0 413 171 B1 discloses agents for the treatment of conditions of severe pain consisting of soft gelatine capsules containing from 30 to 50 parts ibuprofen and from 1.5 to 4 parts bei weight of codein and/or physiologically compatible salts thereof, partially dissolved and partially suspended in 68.5 to 46 parts by weight of polyoxyethylene-polyoxypropylene-diol or in a mixture comprising 30 to 76 parts by weight of polyoxyethylene-polyoxypropylene-diol or polyethyleneglycol or polypropyleneglycol and from 7 to 40 parts by weight of a physiologically compatible surfactant.
  • US-A-5,360,615 discloses a solvent system enhancing the solubility of pharmaceuticals for encapsulation, in particular, for enhancing the solubility of an acidic pharmaceutical agent like ibuprofen to produce a highly concentrated solution suitable for softgel filling comprising 10-80 % polyethylene glycol, a. solubility enhancing amount of either hydroxide or hydrogen ion and 1-20 % by weight of water. Preferably, 0.2-1.0 mole equivalents of hydroxide ion per mole equivalent of acid in an acidic pharmaceutical agent is used.
  • The solution of ibuprofen disclosed in US 5,360,615 as being suitable for filling softgels or two piece capsules, or for tablet formation comprises 40-80 % by weight ibuprofen, 0.1 - 1.5 moles of hydroxide ion per mole of ibuprofen, 1-20 % by weight water, and 4-12 % by weight glycerin or propylene glycol in polyethylene glycol, wherein said hydroxide ion is more preferredly in the range of 0.2-0.5 moles of hydroxide ion per mole of ibuprofen.
  • US-A-5 912 011 discloses a high concentration solvent system to be enclosed in capsules, said system being composed of a) 10-80% by weight acidic medicine, b) 0.1-1.0 mole hydroxide ions for one mole of said medicine, and c) 1-20% by weight water included in polyoxyethylene sorbitan fatty acid ester.
  • US-A-5 376 688 discloses solutions containing acidic, basic and/or amphoteric pharmaceutical agents for encapsulation in gelatin capsules that derive from the Yu, et al. US patent No. 5,071,643 . US patent No. 5,071,643 discloses a solvent system for enhancing the solubility of an acidic pharmaceutical agent to produce a highly concentrated solution suitable for soft gel filling comprising 10-80% polyethylene glycol, a solubility enhancing amount of hydroxide ion, preferably 0.2-1.0 mole equivalents of hydroxide ion per mole equivalent of acid in an acidic pharmaceutical agent, and 1-20% by weight of water.
  • At the end of the specification, US-A-5 376 688 provides that water may be included in the solution up to about 20% by weight of the solution, More preferably between about 1% up to about 10% by weight of the solution. D2 further discloses that the pharmaceutically acceptable solution can be encapsulated into conventional soft gelatin capsules in accordance with the rotary die process. Alternatively, semi-solid or solid solutions can be appropriately encapsulated in hard shell gelatin capsules as well as soft gelatin capsules. All the examples disclose filling soft gelatin capsules. Example 5 discloses aqueous compositions but does not precise what kind of capsules are filled with the compositions.
  • It is one object of the present invention to provide a pharmaceutically acceptable clear solution for filling hard capsules which overcomes the above disadvantages of the prior art. The filled capsules should be usable as medicaments that can be readily taken and that may contain high concentrations of ibuprofen in a carrier, that are simple to prepare and that will quickly display a high activity. The solutions for filling hard gelatin capsules should show an increased stability and bioavailability of ibuprofen.
  • Hard shell capsules are two piece pharmaceutical capsules with shells consisting generally of known film forming materials or compositions. Suitable film forming material can be a hydrophilic polymer, gelatin being the preferred choice. Other suitable capsule shell materials include starch, modified starches like hydroxypropylated hydroxyethylated starches, casein, chitosan, soya bean protein, safflower protein, alginates, gellan gum, carrageenan, xanthan gum, pullulan, phthalated gelatin, succinated gelatin, cellulosephtalate-acetate, polyvinylalcohol, polyvinylacetate, hydroxypropyl methylcellulose, polyvinylacetate-phtalate, polymerisates of acrylic or mthacrylic esters or mixtures thereof. The capsule shell material may furthermore contain 0 to 40 % pharmaceutically acceptable plasticizers based upon the weight of the hydrophilic polymer. The plasticizer which may be employed can be selected from polyethylene glycol, glycerol, sorbitol, dioctyl-sodium sulfosuccinate, triethyl citrate, tributyl citrate, 1,2-propyleneglycol, mono-, di, or tri-acetates of glycerol or mixtures thereof.
  • Additionally, the capsule shell material can contain 0 to 10 % pharmaceutically acceptable lubricants based upon the weight of the hydrophilic polymer. The lubricate may be selected from aluminiumstearate, calciumstearate, magnesiumstearate, tinstearate, talc, sodium lauryl sulfate, lecithins, mineral oils, stearic acid or silicones or mixtures thereof.
  • Moreover, the capsule shell material can contain 0 to 10 % pharmaceutically acceptable coloring agents based upon the weight of the hydrophilic polymer. The coloring agent may be selected from azo-quinophthalone-, triphenylmethane-, xanthene-dyes, iron oxides or hydroxides, titanium dioxide or natural dyes or mixtures thereof. Further suitable coloring agents are sunset yellow, allura red, amaranth, cochineal red, azogeranine, tartrazine, brilliant black, canthaxanthin, patent blue, fast green, brilliant blue, acid green, erythrosine, quinoline yellow, indigotine, curcumin or carbon black.
  • Furthermore, the capsule shell material contains 0 to 95 % pharmaceutically acceptable extenders based upon the weight of the hydrophilic polymer. The extender may be selected from sunflower proteins, soybean proteins, cotton seed proteins, peanut proteins, rape seed proteins, lactose, gum arabic, acrylates or methacrylates, cellulose acetyl phthalates, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulosephthalate, hydroxymethylcellulose, polyvinylpyrrolidone, shellac, bentonite, polyvinyl-acetatephtalate, phthalated gelatin, succinated gelatin, agar agar, hydroxyalkylstarches or mixtures thereof.
  • The solid pharmaceutical dosage form according to the present invention also may comprise a coating selected from cellacephate, polyvinyl acetate phthalate, methacrylic acid polymers, hypromellose phthalate, hydroxyalkyl methyl cellulose phthalates or mixtures thereof.
  • Preferably the film forming composition is suitable for the manufacture of clear transparent hard capsules by conventional dip molding process on high speed production equipment.
  • Accordingly, the present invention provides pharmaceutically acceptable solutions, which are preferably clear transparent, for filling hard shell capsules comprising, based upon the total weight of the solution,
    1. a) from 35 to 75 % by weight ibuprofen,
    2. b) from 1 to 10 % by weight alkali hydroxide, and
    3. c) from 15 to 55 % by weight of an emulsifier selected from polyoxyethylene alkyl ethers, medium chain triglycerides, propylene glycol esters, glyceryl esters, sorbitan esters, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, castor oil, or mixtures therof,
    wherein the molar ratio between alkali hydroxide b)and ibuprofen a) is from 0.1 to 0.5.
  • The present invention furthermore provides an ibuprofen-containing hard shell capsule, preferably clear transparent, containing a solution which comprises, based upon the total weight of the solution,
    1. a) from 35 to 75 % by weight ibuprofen,
    2. b) from 1 to 10 % by weight alkali hydroxide, and
    3. c) from 15 to 55 % by weight of an emulsifier selected from polyoxyethylene alkyl ethers, medium chain triglycerides, propylene glycol esters, glyceryl esters, sorbitan esters, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, castor oil, or mixtures therof,
    wherein the molar ratio between alkali hydroxide b)and ibuprofen a) is from 0.1 to 0.5.
  • As component a) ibuprofen is used according to the invention in an amount of from 35 to 75 % by weight, preferably 40 to 55 % by weight, most preferably 45 to 50 by weight, with respect to the total weight of the solution.
  • In the present invention ibuprofen is in general used as racemic mixture.
  • As component b) alkali hydroxide is used in an amount of from 1 to 10 % by weight, preferably 1 to 5 % by weight, with respect to the total weight of the solution.
  • The alkali hydroxide used as component b) in the present invention is preferably sodium hydroxide (NaOH), potassium hydroxide (KOH) or their mixture. The most preferred alkali hydroxide according to the invention is KOH.
  • In a preferred embodiment of the invention KOH is used in an amount of from 0.2 to 0.35 moles per mol ibuprofen, i.e., 0.2 to 0.35 mole equivalents of alkali hydroxide per mole of the pharmaceutical agent ibuprofen.
  • As component c) according to the invention 15 to 55 % by weight, with respect to the total weight of the solution, emulsifiers selected from polyoxyethylene alkyl ethers, medium chain triglycerides, propylene glycol esters, glyceryl esters, sorbitan esters, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, or mixtures therof are used.
  • Preferred polyoxethylene alkyl ethers according to the invention are polyoxyl 2 cetyl ether, polyoxyl 10 cetyl ether, polyoxyl 20 cetyl ether, polyoxyl 4 lauryl ether, polyoxyl 23 lauryl ether, polyoxyl 2 oleyl ether, polyoxyl 10 oleyl ether, polyoxyl 20 oleyl ether, polyoxyl 2 stearyl ether, polyoxyl 10 stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 100 stearyl ether or polyoxyl 20 cetostearyl ether.
  • Preferred medium chain triglycerides are caprylic/capric triglycerides like MTC oil, Miglyol® 810 or Miglyol® 812. Especially preferred is Miglyol® 812.
  • Preferred propylene glycol ester are propylene glycol propylene glycol dicocoate, propylene glycol distearate, propylene glycol dioctanoate, propylene glycol dipelargonate, propylene glycol diundecanoate, propylene glycol monostearate, propylene glycol monohydroxystearate, propylene glycol monolaurate, propylene glycol monomyristate, or propylene glycol monooleate. Especially preferred is propylene glycol monolaurate.
  • Preferred glyceryl esters are glyceryl monooleate, glyceryl monostearate or glyceryl palmitostearate. Especially preferred is glyceryl monooleate.
  • Preferred sorbitan ester are sorbitan di-isostearate, sorbitan dioleate, sorbitan monolaurate, sorbitan monoisostearate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesqui-isostearate, sorbitan sesquioleate, sorbitan sesquistearate, sorbitan tri-isostearate, sorbitan trioleate or sorbitan tristearate. Especially preferred is sorbitan trioleate.
  • Preferred polyoxyethylene castor oil derivatives are polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, polyoxyl 40 castor oil, polyoxyl 40 hydrogenated castor oil or polyoxyl 60 hydrogenated castor oil. Especially preferred are polyoxyl 35 castor oil (Cremophor® EL) or polyoxyl 40 hydrogenated castor oil (Cremophor® RH40).
  • Preferred polyoxyethylene sorbitan fatty acid esters are polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polysorbate 81, polysorbate 85 or polysorbate 120. Especially preferred is polysorbate 60.
  • Preferred polyoxyethylene stearates are polyoxyl 6 stearate, polyoxyl 8 stearate, polyoxyl 12 stearate or polyoxyl 20 stearate.
  • The density of the emulsifier c) may vary over a broad range, but is generally in the range of from 0.85 to 1.1 at 60°C.
  • Preferably, the emulsifier c) is a polyoxyethylene castor oil derivative, especially preferred polyoxyl 35 castor oil (Cremophor® EL) or polyoxyl 40 hydrogenated castor oil (Cremophor® RH40) in an amount of from 40 to 55, in particular 45 to 50 % by weight of the whole composition.
  • In an especially preferred embodiment the polyoxyethylene castor oil derivative is used in an amount from 10 to 40 %, more preferably from 15 to 35 % by weight in admixture with medium chain triglycerides from 7 to 35 % by weight, preferably 10 to 25 % by weight, most preferably 12 to 18 % by weight of the whole composition and whereby the caprylic/capric triglyceride Miglyol® 812 is especially preferred.
  • The solution according to the present invention comprising components a), b) and c) and/or water and/or other ingredients is preferably clear transparent and has in general a viscosity at 25°C in the range of from 500 to 5000 cps, preferably of from 1000 to 4000 cps, and most preferably of from 1200 to 2500 cps.
  • In one aspect the present invention provides an ibuprofen-containing hard shell capsule containing the aforementioned solution comprising components a) to c) and/or water and/or other ingredients.
  • The hard shell capsule is a system comprised of the ibuprofen formulation and the capsule shell used to encapsulate the ibuprofen formulation. As such, not only is the filled ibuprofen formulation critical to produce the desired bioavailability characteristics but the shell composition is also critical as it must be compatible with the ibuprofen formulation. The potential fill-shell interactions could result in both physical and chemical capsule instability. Accordingly, the shell composition utilized to form the capsule for the ibuprofen dosage form is also critical to the present invention.
  • Therefore, the present invention utilizes a hard shell capsule consisting of the aforementioned film forming material.
  • Preferably, the capsule of the present invention is clear transparent.
  • Hard shell capsules for liquid filling have usually a volume of from 0.3 to 1.0 ml. The available volume is in general from 85-95 vol-%. In comparison to soft capsules, the moisture uptake of hard shell capsules is usually much lower than of soft capsules.
  • In the hard capsule encapsulation process the capsule is usually pre-fabricated and supplied empty, whereas in the soft capsule the encapsulation and filling take place simultaneously.
  • Various methods can be used to seal the hard shell capsules according to the invention. Preferred methods ar banding using a band consisting of a film forming material as aforementioned for the capsul shell, and sealing using a hydroalcoholic solution.
  • The banding of hard shell capsules is well-known in the art. The capsules are first rectified and then passed once or twice over a whell that revolves in a gelatin bath. An amount of gelatin is picked up by the serrated wheel and applied to the junction of the cap and body. The capsules remain in individual carries for drying.
  • According to the invention the hard shell capsule sealing is preferred which is based upon the lowering of the melting point of gelatin by the application of moisture to the area between the capsule body and cap.
  • In a preferred embodiment of the present invention a method is thus contemplated where the capsules are filled and then sealed by spraying a small amount of a water/ethanol mixture at the cap and body interface followed by warming to fuse the two capsule part together.
  • Instrumentation for performing the encapsulation according to the above methods is commercially available.
  • The capsules of the present invention did not show any capsule brittleness as determined according to Cadé and Madit, in "Liquid Filling in Hard Gelatin Capsules - Preliminary Steps", Bulletin Technique Gattefossé, 1996, when stored at 30% and 50% relative humidity for four weeks.
  • Using the solution of the present invention, it is possible to prepare a unit dose of ibuprofen in a two piece hard shell capsule, wherein the fill solution contains a therapeutically effective amount of ibuprofen dissolved within. The dosages administered will vary depending upon the acidic pharmaceutical agent employed, the mode of administration the treatment desired, the size, age, and weight of the patient being treated and the like.
  • The invention will be further illustrated by the following non-limiting examples. Percentages given therein refer to the total weight of the solution.
    • Examples Example 1
  • Example 1
    mg/caps %
    Ibuprofen 200.00 47.62
    Cremophor® RH40 140.71 33.50
    Miglyol® 812 63.00 15.00
    KOH 16.29 3.88
    420.00 100
  • In Example 1 0.3 mol equiv KOH and 15 % Miglyol® were used. The viscosity at 25°C was 1900 cps and at 35°C 836 cps.
    Example 2
    mg/caps %
    Ibuprofen 200.00 47.62
    Cremophor® EL 140.71 33.50
    Miglyol® 812 63.00 15.00
    KOH 16.29 3.88
    420.00 100
  • In Example 2 0.3 mol equiv KOH/ 15 % Miglyol® were used. The viscosity was 3140 cp at 25 °C.
  • Similarly to Examples 1 and 2 examples were produced which corresponded to the following compositions.
    Example 3
    mg/caps %
    Ibuprofen 201.78 48.04
    Cremophor® EL or RH 40 201.78 48,04
    Miglyol® 812 - -
    KOH 16.44 3,92
    420.00 100
    Examples 4 and 5
    mg/caps %
    Ibuprofen 201.43 38,74
    Cremophor® EL (Example 4) or RH40 (Ex. 5) 151,07 29,05
    Miglyol® 812 151,07 29,05
    KOH 16,42 3,16
    520.00 100

Claims (6)

  1. A pharmaceutically acceptable composition for liquid filling hard shell capsules comprising, based upon the total weight of the composition.
    a) from 35 to 75 % by weight ibuprofen,
    b) from 1 to 10 % by weight alkali hydroxide, and
    c) an emulsifier which is a polyoxyethylene castor oil derivative in an amount from 10 to 40 % by weight in admixture with caprylic/capric triglycerides from 7 to 35 % by weight of the whole composition, and
    wherein the molar ratio between alkali hydroxide b) and ibuprofen a) is from 0.1 to 0.5.
  2. The pharmaceutical composition according to claim 1, wherein the emulsifier c) is a mixture of polyoxyl 35 castor oil or polyoxyl 40 hydrogenated castor oil with caprylic/capric triglyceride.
  3. The pharmaceutical composition according to claim 1, wherein the polyoxyethylene castor oil derivative is contained in an amount from 15 to 35 % by weight and the caprylic/capric triglycerides is contained in an amount from 12 to 18 % by weight.
  4. A liquid filled pharmaceutical hard shell capsule containing a composition which comprises, based upon the total weight of the composition,
    a) from 35 to 75 % by weight ibuprofen,
    b) from 1 to 10 % by weight alkali hydroxide, and
    c) an emulsifier which is a polyoxyethylene castor oil derivative in an amount from 10 to 40 % by weight in admixture with caprylic/capric triglycerides from 7 to 35 % by weight of the whole composition, and
    wherein the molar ratio between alkali hydroxide b) and ibuprofen a) is from 0.1 to 0. 5.
  5. A liquid filled pharmaceutical hard capsule containing a composition according to claim 2.
  6. A liquid filled pharmaceutical hard capsule containing a composition according to claim 3
EP03743950A 2002-03-11 2003-02-28 Ibuprofen solution for hard shell capsules Expired - Lifetime EP1485081B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP03743950A EP1485081B1 (en) 2002-03-11 2003-02-28 Ibuprofen solution for hard shell capsules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02290595 2002-03-11
EP02290595A EP1344523A1 (en) 2002-03-11 2002-03-11 Ibuprofen solution for hard gelatin capsules
EP03743950A EP1485081B1 (en) 2002-03-11 2003-02-28 Ibuprofen solution for hard shell capsules
PCT/IB2003/000796 WO2003075909A1 (en) 2002-03-11 2003-02-28 Ibuprofen solution for hard shell capsules

Publications (2)

Publication Number Publication Date
EP1485081A1 EP1485081A1 (en) 2004-12-15
EP1485081B1 true EP1485081B1 (en) 2010-05-05

Family

ID=27763452

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02290595A Withdrawn EP1344523A1 (en) 2002-03-11 2002-03-11 Ibuprofen solution for hard gelatin capsules
EP03743950A Expired - Lifetime EP1485081B1 (en) 2002-03-11 2003-02-28 Ibuprofen solution for hard shell capsules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP02290595A Withdrawn EP1344523A1 (en) 2002-03-11 2002-03-11 Ibuprofen solution for hard gelatin capsules

Country Status (15)

Country Link
US (1) US7229639B2 (en)
EP (2) EP1344523A1 (en)
JP (2) JP4818587B2 (en)
KR (1) KR100679582B1 (en)
CN (1) CN1642537A (en)
AT (1) ATE466575T1 (en)
AU (1) AU2003215775A1 (en)
BR (1) BR0308348A (en)
CA (1) CA2477393A1 (en)
DE (1) DE60332432D1 (en)
EA (1) EA200401067A1 (en)
ES (1) ES2342825T3 (en)
MX (1) MXPA04008151A (en)
NZ (1) NZ534928A (en)
WO (1) WO2003075909A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules
DK2279729T3 (en) * 2003-07-17 2016-11-28 Banner Life Sciences Llc Control release preparations
US20070071808A1 (en) * 2003-08-28 2007-03-29 Janik John J Capsule filled with honey
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
CA2552611A1 (en) * 2004-01-09 2005-08-04 Wyeth Microemulsions for pharmaceutical compositions
US20080075767A1 (en) * 2006-06-30 2008-03-27 Jin Xiao P Ibuprofen-containing liquid filled hard capsules
KR101236528B1 (en) * 2010-06-07 2013-02-22 한국콜마주식회사 Sealed hardcapsule containing liquid composition of dexibuprofen
KR101346750B1 (en) * 2010-06-07 2013-12-31 한국콜마주식회사 Sealed hardcapsule containing liquid composition of naproxen
US9044394B2 (en) * 2010-10-18 2015-06-02 PruGen IP Holdings, Inc. Bioavailability enhancement delivery composition
EP3566698A1 (en) 2011-11-09 2019-11-13 Capsugel Belgium NV Acid resistant banding solution for acid resistant two piece hard capsules
EP3566699A1 (en) 2015-11-10 2019-11-13 Capsugel Belgium NV Acid resistant banding or sealing solution for acid resistant two piece hard capsules
WO2018008660A1 (en) * 2016-07-06 2018-01-11 クオリカプス株式会社 Hard capsule having improved hardness, and method for manufacturing same
US20210353573A1 (en) 2018-10-08 2021-11-18 Chanelle Pharmaceuticals Manufacturing Ltd. A soft-gel capsule formulation, method of manufacture and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
JP3121080B2 (en) * 1991-12-19 2000-12-25 アール・ピー・シーラー コーポレイション Encapsulation solution
US5376688A (en) * 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
US5831108A (en) * 1995-08-03 1998-11-03 California Institute Of Technology High metathesis activity ruthenium and osmium metal carbene complexes
GB9605948D0 (en) * 1996-03-21 1996-05-22 Smithkline Beecham Plc Novel formulations
ES2236891T3 (en) * 1997-03-12 2005-07-16 Abbott Laboratories HYDROFILE BINARY SYSTEMS FOR THE ADMINISTRATION OF CYCLOSPORINE.
US6221391B1 (en) * 1998-11-23 2001-04-24 Accucaps Industries Limited Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules

Also Published As

Publication number Publication date
DE60332432D1 (en) 2010-06-17
CA2477393A1 (en) 2003-09-18
JP2005526758A (en) 2005-09-08
EP1344523A1 (en) 2003-09-17
WO2003075909A1 (en) 2003-09-18
CN1642537A (en) 2005-07-20
ATE466575T1 (en) 2010-05-15
AU2003215775A1 (en) 2003-09-22
MXPA04008151A (en) 2004-11-26
EA200401067A1 (en) 2004-12-30
NZ534928A (en) 2006-09-29
KR100679582B1 (en) 2007-02-07
BR0308348A (en) 2005-01-25
US20030211145A1 (en) 2003-11-13
US7229639B2 (en) 2007-06-12
EP1485081A1 (en) 2004-12-15
KR20040101300A (en) 2004-12-02
JP2009197015A (en) 2009-09-03
JP4818587B2 (en) 2011-11-16
ES2342825T3 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
JP2009197015A (en) Ibuprofen solution for hard shell capsule
US6491950B1 (en) Controlled release pharmaceutical composition
TWI490216B (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
US6596308B2 (en) Controlled release pharmaceutical composition
EP1207872B1 (en) Ibuprofen-containing softgels
JP2005518423A (en) Pharmaceutical composition for hepatitis C virus protease inhibitor
US20030232097A1 (en) Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
JP6276756B2 (en) 1,1-dimethylethyl [(1S) -1-{[(2S, 4R) -4- (7-chloro-4methoxyisoquinolin-1-yloxy) -2-({(1R, 2S) -1- [ Solubilized capsule formulation of (cyclopropylsulfonyl) carbamoyl] -2-ethenylcyclopropyl} carbamoyl) pyrrolidin-1-yl] carbonyl} -2,2-dimethylpropyl] carbamate
WO2009069139A1 (en) Dosage form providing an ibuprofen-containing liquid fill
EP1765353A1 (en) Solid orally ingestible formulations of tetrodotoxin
MX2012008300A (en) Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof.
EP1453489B1 (en) Acetaminophen compositions
SK7342000A3 (en) Formulations comprising dissolved paroxetine
KR101859200B1 (en) Pharmaceutical composition of monoacetyldiacylglycerol compound for oral administration and solid pharmaceutical preparation
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
WO2016126540A1 (en) Stabilized dialkyl fumarate compositions
US20040146537A1 (en) Oily wax matrix suspension formulation comprising pharmacologically active agents
JPH0892088A (en) Oily composition for oral administration
US20060286164A1 (en) Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
JP2008150298A (en) Diphenhydramine-containing medicine composition having improved solubility
WO2005032516A1 (en) Formulation and manufacturing process of self-microemulsified aceclofenac soft capsules
JPH07267875A (en) Liquid preparation containing high concentration of aureobasidin
JP2000355552A (en) Oxatomide pharmaceutical preparation
CZ20001876A3 (en) Preparations containing dissolved paroxetine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041011

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MADIT, NICOLAS

Inventor name: GUILLARD, E. M.,EMANUELLE MIREILLE

Inventor name: SCOTT, ROBERT A.

17Q First examination report despatched

Effective date: 20050114

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WARNER-LAMBERT COMPANY LLC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUILLARD, E. M.,EMMANUELLE MIREILLE

Inventor name: MADIT, NICOLAS

Inventor name: SCOTT, ROBERT A.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60332432

Country of ref document: DE

Date of ref document: 20100617

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2342825

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100505

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100906

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110208

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60332432

Country of ref document: DE

Effective date: 20110207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20120105 AND 20120111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 60332432

Country of ref document: DE

Owner name: CAPSUGEL BELGIUM NV, BE

Free format text: FORMER OWNER: WARNER-LAMBERT COMPANY LLC, NEW YORK, N.Y., US

Effective date: 20120202

Ref country code: DE

Ref legal event code: R082

Ref document number: 60332432

Country of ref document: DE

Representative=s name: KRAUS & WEISERT PATENTANWAELTE PARTGMBB, DE

Effective date: 20120202

Ref country code: DE

Ref legal event code: R081

Ref document number: 60332432

Country of ref document: DE

Owner name: CAPSUGEL BELGIUM NV, BE

Free format text: FORMER OWNER: WARNER-LAMBERT COMPANY LLC, NEW YORK, US

Effective date: 20120202

Ref country code: DE

Ref legal event code: R082

Ref document number: 60332432

Country of ref document: DE

Representative=s name: PATENT- UND RECHTSANWAELTE KRAUS & WEISERT, DE

Effective date: 20120202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100805

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20140113

Year of fee payment: 12

Ref country code: IT

Payment date: 20140212

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20150227

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150126

Year of fee payment: 13

Ref country code: FR

Payment date: 20150126

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150228

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150301

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60332432

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160228

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20161028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160901

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160228